MRVI

#2032
Maravai LifeSciences Holdings, Inc. - Class A common stock
7.3 0 USD
-0.04%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
7.30
7.30
Jahresspanne
2.30
9.42
Tagesänderung
-4.45%
Monatliche Änderung
+10.61%
6 month change
+108.57%
Jahresänderung
+211.97%
Vorheriger Schlusskurs
7.6 4
Open
7.3 0
Tief
7.3 0
Hoch
7.3 0
Volumen
204
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
MARAVAI LIFESCIENCES HOLDINGS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
MARAVAI LIFESCIENCES HOLDINGS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
MARAVAI LIFESCIENCES HOLDINGS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MARAVAI LIFESCIENCES HOLDINGS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MARAVAI LIFESCIENCES HOLDINGS, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
MARAVAI LIFESCIENCES HOLDINGS, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
MARAVAI LIFESCIENCES HOLDINGS, INC. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
MARAVAI LIFESCIENCES HOLDINGS, INC. annual report, FY2025
10-K
Current report, Q4 FY2025
MARAVAI LIFESCIENCES HOLDINGS, INC. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
MARAVAI LIFESCIENCES HOLDINGS, INC. current report, Q4 FY2025
8-K

MARAVAI LIFESCIENCES HOLDINGS, INC. current report, Q2 FY2025

Full document

Business Context and Reporting Period

This Form 8-K reports the results of the 2025 Annual Meeting of Shareholders held by Maravai LifeSciences Holdings, Inc. on May 22, 2025. The record date for the meeting was March 24, 2025, with 254,642,249 shares of common stock issued and outstanding (143,958,169 Class A and 110,684,080 Class B). A quorum was established with 231,686,324 shares present.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.

Material Changes and Voting Results

Shareholders voted on three proposals at the Annual Meeting:

  • Proposal 1: Election of Directors. All four nominees were elected to three-year terms expiring in 2028.
    • Sean Cunningham: 185,635,895 votes For; 23,897,811 votes Withheld.
    • John DeFord, Ph.D.: 195,101,055 votes For; 14,432,651 votes Withheld.
    • Jessica Hopfield, Ph.D.: 185,887,446 votes For; 23,646,260 votes Withheld.
    • Murali K. Prahalad, Ph.D.: 189,100,818 votes For; 20,432,888 votes Withheld.
  • Proposal 2: Ratification of Auditors. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2025, was ratified.
    • Votes For: 230,018,925
    • Votes Against: 457,700
    • Abstentions: 1,209,699
  • Proposal 3: Executive Compensation (Say-on-Pay). Shareholders approved, on a non-binding advisory basis, the compensation of named executive officers.
    • Votes For: 169,521,411
    • Votes Against: 37,367,937
    • Abstentions: 2,644,358

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.

Key Facts for Investor Verification

  • Verify the specific terms of the three-year director mandates expiring in 2028.
  • Confirm the engagement scope and fees for Ernst & Young LLP for the fiscal year ending December 31, 2025.
  • Review the detailed executive compensation disclosures referenced in the proxy statement to understand the basis for the "Say-on-Pay" vote results.
  • Note the significant number of broker non-votes (22,152,617.85) on the director election and executive compensation proposals.

Nachrichten